[RANKL as a target molecule for treatment of joint destruction]

Clin Calcium. 2007 Apr;17(4):586-92.
[Article in Japanese]

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized progressive joint destruction. Recent studies have revealed an essential role of receptor activator of NF-kappaB ligand (RANKL) in bone destruction in RA, and therapeutics targeting RANKL has been attracting a great deal of attention.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / etiology*
  • Arthritis, Rheumatoid / pathology
  • Bone Remodeling
  • Bone and Bones / pathology
  • Cell Differentiation / genetics
  • Drug Design*
  • Humans
  • Osteoclasts / cytology
  • Osteoclasts / physiology
  • RANK Ligand / physiology*
  • Tumor Necrosis Factor-alpha / physiology

Substances

  • RANK Ligand
  • Tumor Necrosis Factor-alpha